Preferential enzymatic activation of distinct TSNAs, NNK by CYP2B6 and NNN by CYP2A6 [8,9], may underlie the observed independent contributions of these genes to lung cancer risk. This evidence concerns the gene CYP2A6 and lung carcinoma.